A novel myeloid cell line, Marimo, derived from therapy-related acute myeloid leukemia during treatment of essential thrombocythemia: consistent chromosomal abnormalities and temporary C-MYC gene amplification.
A novel myeloid leukemia cell line, Marimo, was established from bone marrow cells of a patient with secondary acute myeloid leukemia (AML) that had developed during the treatment of essential thrombocythemia (ET) with busulfan. Karyotype at the ET phase was 46,XX,der(15)t(1;15) (q23;p12-13), but at the blastic phase changed to 44,XX,-5,del(8)(q22), add(17)(p11),+18, psu dic(18;9) (q23;p21) x 2 lacking t(1;15). In Marimo cells, C-MYC gene was temporarily amplified by double-minutes (dmin) but disappeared at 33 months, whereas t(10;14;11)(q22;q32;q13) and t(10;14)(q22;q32) were added in vitro psu dic(18;9) x 2 and add(17)(p11) were consistently found throughout the culture. These results suggest that this AML clone is not derived from ET but rather is therapy-related.
Yoshida
H
H
Department of Infectious Diseases, Nagoya University Hospital, Japan.
Kondo
M
M
Ichihashi
T
T
Hashimoto
N
N
Inazawa
J
J
Ohno
R
R
Naoe
T
T
D002460:Cell Line; D002869:Chromosome Aberrations; D005260:Female; D005784:Gene Amplification; D016259:Genes, myc; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000235:genetics*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000235:genetics*; D013922:Thrombocytosis / Q000188:drug therapy*